Condor Capital Management’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Condor Capital Management’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-43,000	Closed	-$23K	–	190
2019 Q4	$23K	Buy	43,000 +29,000	+207%	+$70.3K	﹤0.01%	183
2019 Q3	$53K	Hold	14,000	–	–	0.01%	183
2019 Q2	$93K	Buy	+14,000	New	+$53.3K	0.01%	184
2019 Q1	–	Sell	-14,000	Closed	-$55K	–	191
2018 Q4	$55K	Buy	+14,000	New	+$179K	0.01%	182

Condor Capital Management's MLNT Position: Q1 2020 in Review

Condor Capital Management sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 43,000 shares — an estimated $23K sold.

Condor Capital Management first reported a position in MLNT in Q4 2018 and held it in 4 quarters. The position peaked at $93K in Q2 2019. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

Condor Capital Management reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Condor Capital Management sold 43,000 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $23K.
Condor Capital Management first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2018 and held it in 4 quarters.
Condor Capital Management's Melinta Therapeutics, Inc. Common Stock position peaked at $93K in Q2 2019.
2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Condor Capital Management's 13F filing for Q1 2020, filed 7 May 2020.